The prognosis of PAD patients with heart failure also depended on the type of heart failure (reduced ejection fraction vs. preserved ejection fraction) as well as on the associated treatment, considering the beneficial role of SGLT2 inhibitors on the prognosis of patients with heart failure regardless of the presence or absence of diabetes mellitus [61]. This evidence concerns the gene SLC5A2 and heart failure.